Beta2-agonist impairs muscle insulin sensitivity in persons with insulin resistance.

Johan D Onslev Matteo Fiorenza Martin Thomassen Jesper Foged HavelundJens BangsboNils FærgemanJørgen F P Wojtaszewski Morten Hostrup

Published in: The Journal of clinical endocrinology and metabolism (2024)

Our findings suggest that beta2-agonist inhibits glycogenesis while intralipid inhibits glycolysis in skeletal muscle of insulin-resistant individuals. These results should be addressed in future treatment of insulin resistance with beta2-agonist.

Keyphrases

insulin resistance
skeletal muscle
type diabetes
high fat diet
adipose tissue
metabolic syndrome
polycystic ovary syndrome
high fat diet induced
glycemic control
replacement therapy
smoking cessation